Enhancing translation: guidelines for standard pre-clinical experiments in mdx mice
about
Pre-clinical drug tests in the mdx mouse as a model of dystrophinopathies: an overviewThreats to validity in the design and conduct of preclinical efficacy studies: a systematic review of guidelines for in vivo animal experimentsDistinguishing between exploratory and confirmatory preclinical research will improve translationThe mdx mouse model as a surrogate for Duchenne muscular dystrophySelective modulation through the glucocorticoid receptor ameliorates muscle pathology in mdx micePharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trialsAssessing functional performance in the mdx mouse modelVentilatory chemosensory drive is blunted in the mdx mouse model of Duchenne Muscular Dystrophy (DMD).VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects.Dystropathology increases energy expenditure and protein turnover in the mdx mouse model of duchenne muscular dystrophyNaproxcinod shows significant advantages over naproxen in the mdx model of Duchenne Muscular Dystrophy.Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy.A necrotic stimulus is required to maximize matrix-mediated myogenesis in mice'IRDiRC Recognized Resources': a new mechanism to support scientists to conduct efficient, high-quality research for rare diseases.Nutrition strategies to improve physical capabilities in Duchenne muscular dystrophy.Increased levels of interleukin-6 exacerbate the dystrophic phenotype in mdx mice.Gene expression in mdx mouse muscle in relation to age and exercise: aberrant mechanical-metabolic coupling and implications for pre-clinical studies in Duchenne muscular dystrophy.Long-term Exon Skipping Studies With 2'-O-Methyl Phosphorothioate Antisense Oligonucleotides in Dystrophic Mouse Models.Quantitative assessment of muscle damage in the mdx mouse model of Duchenne muscular dystrophy using polarization-sensitive optical coherence tomography.Contractile efficiency of dystrophic mdx mouse muscle: in vivo and ex vivo assessment of adaptation to exercise of functional end points.Are mice good models for human neuromuscular disease? Comparing muscle excursions in walking between mice and humans.Natural History, Trial Readiness and Gene Discovery: Advances in Patient Registries for Neuromuscular Disease.Skeletal Muscle Differentiation on a Chip Shows Human Donor Mesoangioblasts' Efficiency in Restoring Dystrophin in a Duchenne Muscular Dystrophy Model.Ryanodine channel complex stabilizer compound S48168/ARM210 as a disease modifier in dystrophin-deficient mdx mice: proof-of-concept study and independent validation of efficacy.Low-intensity training provokes adaptive extracellular matrix turnover of a muscular dystrophy model.Muscle dysfunction caused by loss of Magel2 in a mouse model of Prader-Willi and Schaaf-Yang syndromes.The dual CCR2/CCR5 chemokine receptor antagonist Cenicriviroc reduces macrophage infiltration and disease severity in Duchenne muscular dystrophy (Dmdmdx-4Cv) mice.Update on Standard Operating Procedures in Preclinical Research for DMD and SMA Report of TREAT-NMD Alliance Workshop, Schiphol Airport, 26 April 2015, The Netherlands.
P2860
Q26849430-EDE5B0FD-BC8D-49DF-A60F-108B6E3FF1EDQ28534767-4A65B672-2F3B-4AA1-BC4B-70AD20331945Q28538978-F52121CD-D1CC-4F55-8D7F-CB83E298ABCDQ28656377-8B665C87-FCAF-4629-A489-9A80D34D1D17Q33925571-508F4162-ACE9-4C4D-8655-4411BF6BD91FQ34152280-97AB5B3E-1437-426B-9E63-DFEDB254DD43Q34153862-162972E3-39D9-4849-96E5-9B55E9550BEDQ34903075-ED96BC91-77B9-425B-B546-E43B3693A355Q34981147-8EC4090F-E140-4F41-900F-10F33CE0641BQ35106988-EDD653B0-74BB-4765-8EBE-C9158174F9E4Q35986842-F279536B-045C-4352-93C4-1E579467C903Q36598414-0231E942-E7AB-474F-A2D7-2A7EE34579B3Q36790979-20A5A22C-4B5B-4A84-8BB2-A8DB93064DD2Q37599234-83CE793D-B0CA-4534-91AC-1B6D1F44E648Q37975321-3FEBEB3F-FAF7-4FF2-B446-92FC6AAA4E70Q41045084-F4C4F797-1E07-4972-81F5-E868111BB2B4Q42460420-FD9CEAF7-4AF9-4B49-A360-98CFDBC3C26EQ42507352-8E4DA377-C9AA-4D0C-BC57-AC5E09D83D62Q44298382-8870DD40-270F-4E0A-AB20-82818BB27B22Q45050237-01CC53F6-6A2A-4CF0-A45C-35F8B1EABF9BQ45073133-1F69BFF9-2D74-45D1-AD8B-F24846A4E59DQ45951421-74EDF5C3-CA84-4C1E-98F4-34065E8B611EQ46190014-CD7CF749-7FAD-4152-A15C-C02EA8786D69Q47665947-9CC10061-DBB4-4CA3-A2CA-795A2E9E9D36Q49166095-2793F107-773B-495A-8B15-631FFCB3761CQ51629774-50264A4E-F90C-4AA2-B9FB-779ECC43FF45Q52644936-6DF1F93F-6CD6-4036-B0C5-E9B380EB2695Q55024154-DAAEE5D6-4D80-45A9-98A9-FAB910F4805B
P2860
Enhancing translation: guidelines for standard pre-clinical experiments in mdx mice
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Enhancing translation: guidelines for standard pre-clinical experiments in mdx mice
@ast
Enhancing translation: guidelines for standard pre-clinical experiments in mdx mice
@en
type
label
Enhancing translation: guidelines for standard pre-clinical experiments in mdx mice
@ast
Enhancing translation: guidelines for standard pre-clinical experiments in mdx mice
@en
prefLabel
Enhancing translation: guidelines for standard pre-clinical experiments in mdx mice
@ast
Enhancing translation: guidelines for standard pre-clinical experiments in mdx mice
@en
P2093
P2860
P50
P1476
Enhancing translation: guidelines for standard pre-clinical experiments in mdx mice
@en
P2093
Judith Dubach
Raffaella Willmann
TREAT-NMD Neuromuscular Network
P2860
P356
10.1016/J.NMD.2011.04.012
P577
2011-07-06T00:00:00Z